EGFR and non-small cell lung carcinoma: In this study, we conducted a retrospective study to explore the efficacy and safety of EGFR-TKI plus thymosin in NSCLC patients harboring active EGFR mutations, thereby enhancing the efficacy of EGFR-TKI.